Due to the limited number of included trials , there is insufficient evidence to draw any conclusions about the effectiveness of cardiovascular prophylaxis in reducing mortality and cardiovascular events in people with AAA .
BACKGROUND Pharmacological prophylaxis has been proven to reduce the risk of cardiovascular events in individuals with atherosclerotic occlusive arterial disease .
However , the role of prophylaxis in individuals with abdominal aortic aneurysm ( AAA ) remains unclear .
Several studies have shown that despite successful repair , those people with AAA have a poorer rate of survival than healthy controls .
People with AAA have an increased prevalence of coronary heart disease and risk of cardiovascular events .
Despite this association , little is known about the effectiveness of pharmacological prophylaxis in reducing cardiovascular risk in people with AAA .
This is an up date of a Cochrane review first published in 2014 .
OBJECTIVES To determine the long-term effectiveness of antiplatelet , antihypertensive or lipid-lowering medication in reducing mortality and cardiovascular events in people with abdominal aortic aneurysm ( AAA ) .
The effect of beta-blocker dosing strategy on regulation of perioperative heart rate and clinical outcomes in patients undergoing vascular surgery: a randomized comparison.
The optimal dosing strategy for  perioperative beta-blockers  to safely achieve recommended target heart rates ( HRs ) by current guidelines is not well defined . An HR-titrated perioperative beta-blocker dosing regimen versus a fixed-dose regimen was assessed by clinical outcomes , postoperative heart rate , and beta-blocker-related complications .  Patients ( n = 64 ) scheduled to undergo moderate- to high-risk vascular surgery and without contraindications to beta-blockade were r and omized to either a fixed-dose or HR-titrated beta-blocker dosing schedule . Clinical outcomes and HRs were followed immediately preoperatively to 24 hr postoperatively . A difference in mean HR between the two dosing arms was significant immediately postoperatively ( 70.1 vs. 58.2 bpm for fixed dose and HR-titrated arms , respectively ; p = 0.012 ) but at no other time points . However , the HR-titrated strategy led to a significant reduction in the percentage of HR measurements > 80 bpm ( 34.5 % vs. 16.1 % , p < 0.001 ) and to a significant reduction in absolute HR change ( 17.5 vs. 22.5 bpm , p = 0.034 ) . There were no significant differences in the occurrence of asymptomatic hypotension between the two study arms , and no beta-blocker-related adverse events occurred in either study arm . An aggressive , HR-titrated perioperative beta-blocker dosing strategy was associated with more consistent maintenance of postoperative HRs within the range recommended by current guidelines and did not result in increased drug-related adverse events . The question of what is the best perioperative beta-blocker dosing regimen warrants further evaluation in a large-scale clinical trial
Due to the limited number of included trials , there is insufficient evidence to draw any conclusions about the effectiveness of cardiovascular prophylaxis in reducing mortality and cardiovascular events in people with AAA .
BACKGROUND Pharmacological prophylaxis has been proven to reduce the risk of cardiovascular events in individuals with atherosclerotic occlusive arterial disease .
However , the role of prophylaxis in individuals with abdominal aortic aneurysm ( AAA ) remains unclear .
Several studies have shown that despite successful repair , those people with AAA have a poorer rate of survival than healthy controls .
People with AAA have an increased prevalence of coronary heart disease and risk of cardiovascular events .
Despite this association , little is known about the effectiveness of pharmacological prophylaxis in reducing cardiovascular risk in people with AAA .
This is an up date of a Cochrane review first published in 2014 .
OBJECTIVES To determine the long-term effectiveness of antiplatelet , antihypertensive or lipid-lowering medication in reducing mortality and cardiovascular events in people with abdominal aortic aneurysm ( AAA ) .